Is EMRAF undervalued?

AlphaMadera's AlphaVal page computes Emera Incorporated's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag EMRAF as undervalued, fairly valued, or overvalued.

What is Emera Incorporated's fair value?

Fair value for EMRAF is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value EMRAF?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from EMRAF's most recent reported fundamentals.

EMRAF - Emera Incorporated

Price: -- --

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 85% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Moderate

Trading 28.2% above fair value

Current Price $45.13

Bear Case $30.79 31.8% downside ($30.79 - $45.13) / $45.13 = -31.8% $1.96 × 16x P/E

Fair Value $35.19 22.0% downside ($35.19 - $45.13) / $45.13 = -22.0% $1.96 × 18x P/E

Bull Case $39.59 12.3% downside ($39.59 - $45.13) / $45.13 = -12.3% $1.96 × 20x P/E

Adjust Assumptions

P/E Multiple

17.9x

Adjusted EPS

1.96$

Key Value Driver

Normalized P/E multiple (18x base case)

Implied Market Multiple 23.0x

Plain-Language Summary

Applying a 18x P/E to adjusted EPS of $1.96, the base-case value is $35.19 per share.

Warnings

ℹ Financial statements were converted from CAD into USD using USDCAD at 0.7097 USD per CAD.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples